2024 Volume 35 Issue 1 Pages 53-58
The subjects of this study were 164 patients who were treated with direct oral anticoagulants for venous thromboembolism at our hospital. Group R consisted of 49 patients treated with rivaroxaban, Group A consisted of 97 patients treated with apixaban, and Group E consisted of 18 patients treated with edoxaban. The mean age in Group A (78.0 ys) was significantly older than Groups R (67.2 ys) (p<0.001). The proportion of women was significantly higher in groups A and E than Group R (p=0.026). The mean creatinine clearance in Group A (57.2 mL/min) was significantly lower compared to Group R (78.9 mL/min) and Group E (76.0 mL/min), respectively (p<0.0004), p<0.05. The rate of proximal type thrombus was significantly higher in Group A than groups R and E. The overall C-reactive protein positive rate was higher at 70.7%, but there was no difference between the groups. The average regression period of the thrombus was 8.0 weeks in Group R, 7.6 weeks in the Group A, and 11.2 weeks in the Group E, with no significant difference. The average duration of medication was 6.1 months for Group R, 6.0 months for the Group A, and 7.3 months for the Group E, with no difference observed. No significant difference was observed in the rate of recurrence cases:18.4% in Group R, 11.3% in Group A, and 22.2% in Group E. No cases of major bleeding were observed in all groups. There was no particular difference in the efficacy or safety of DOACs.
